Drugmaker Drops Antitrust Suit Against 'Pharma Bro' Shkreli

Law360 (April 23, 2020, 8:54 PM EDT) -- Incarcerated "pharma bro" Martin Shkreli and his former company Retrophin Inc. have managed to slip claims that they tried to keep a generic competitor to their kidney drug Thiola out of the market, as the would-be rival quietly dropped its suit Wednesday.

There was no word on what precipitated Spring Pharmaceuticals LLC's move to voluntarily dismiss its claims, including whether there was a settlement or possibly a move to amend. Attorneys for the parties did not immediately return a request for comment.

But Retrophin and its former owner Shkreli have been fighting to escape the suit since it was filed more...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!